Prevalence of anti-CarP antibodies and anti-CCP antibody in rheumatoid arthritis (RA) and other connective tissue diseases (CTD).
| Disease | n | Age, mean ± SD | Sex, F/M | Anti-CarP+, n (%) | Anti-CCP+, n (%) |
|---|---|---|---|---|---|
| RA (ACPA+) | 209 | 57.1 ± 13.7 | 166/43 | 112 (53.6) | 209/209 (100) |
| RA (ACPA−) | 56 | 63.0 ± 12.8 | 46/10 | 12 (21.4) | 0/56 (0) |
| SLE | 241 | 41.3 ± 13.4 | 224/17 | 53 (22) | 9/189 (4.8) |
| PM/DM | 41 | 54.1 ± 12.6 | 34/7 | 3 (7.3) | 5/41 (12.2) |
| SSc | 100* | 57.7 ± 13.2 | 94/6 | 23 (23) | 3/61 (4.9) |
| MCTD and overlap syndrome | 47 | 49.8 ± 13.2 | 43/4 | 18 (38.3) | 4/35 (11.4) |
| Primary SS | 73 | 57.9 ± 14.4 | 72/1 | 26 (35.6) | 1/62 (1.6) |
| Vasculitis | 37* | 52.4 ± 17.5 | 29/8 | 8 (21.6) | 2/37 (5.4) |
| BD | 36* | 47.2 ± 14.4 | 24/12 | 3 (8.3) | 3/35 (8.6) |
| AOSD | 13* | 50.7 ± 17.4 | 9/4 | 2 (15.4) | 1/11 (9.1) |
| PMR | 13 | 70.1 ± 10.0 | 9/4 | 1 (7.7) | 1/13 (7.7) |
| SpA | 8* | 46.5 ± 15.2 | 3/5 | 4 (50) | 0/8 (0) |
| Others** | 11* | 52.8 ± 17.9 | 9/2 | 5 (45.5) | 0/3 (0) |
| HC | 80 | ND | ND | 3 (3.8) | 0/12 (0) |
↵* Including 3 overlapping patients (a patient with AOSD and SpA, a patient with BD and relapsing polychondritis in the group of Others, and a patient with SSc and vasculitis). They were counted in both disease groups. Anti-CCP was measured in 493 out of 617 non-RA CTD patients and 12 of HC.
↵** Includes relapsing polychondritis, sarcoidosis, primary antiphospholipid syndrome, and osteoarthritis. Anti-CarP: anti-carbamylated protein; ND: not determined; ACPA: anti-citrullinated protein antibody; anti-CCP: anticyclic citrullinated peptide antibodies; SLE: systemic lupus erythematosus; PM/DM: polymyositis/dermatomyositis; SSc: systemic sclerosis; MCTD: mixed CTD; SS: Sjögren syndrome; BD: Behçet disease; AOSD: adult-onset Still disease; PMR: polymyalgia rheumatica; SpA: spondyloarthritis; HC: healthy controls.